Human pharmacology of a low‐molecular‐weight heparin (ALFA‐LMWH): An update

Dettori, A G; Babbini, M.

doi:10.1002/med.2610120404

Cited by 12 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies in healthy volunteers showed that parnaparin inhibits factor Xa (antithrombotic effect) more efficiently than factor IIa (anticoagulant effect), resulting in a greater anti-Xa/anti-IIa activity ratio than UFH 10–12. The inhibition of factor Xa occurs intensively and rapidly (anti-Xa activity about 0.2, 0.5 and 0.9 aXaU/mL, approximatively 2 to 4 hours after administration of parnaparin 3200, 6400 and 12800 IUaXa, respectively), is dose-dependent, and persists for many hours after administration of a single bolus of subcutaneous parnaparin (ranging from 6 to 12 hours after administration of parnaparin 3200 or 6400 IUaXa, with demonstrable anti-Xa activity still occurring at 20 hours with the parnaparin 6400 IUaXa dose; in contrast, the anti-IIa activity was undetectable at 4, 8 and 12 hours postadministration) 11…”

Section: Pharmacology Of Parnaparinmentioning

confidence: 99%

“…In healthy volunteers the peak inhibition of factor Xa (E max ) after subcutaneous administration of parnaparin is dose-dependent (0.27 IU/mL after administration of 3200 IUaXa, 0.58 IU/mL with 6400 IUaXa) 10–12. After intravenous administration E max is approximately 5-fold greater than after subcutaneous administration of the same dose (eg, mean E max 1.35 IU/mL after iv administration of 3200 IUaXa) 10,12.…”

Section: Pharmacology Of Parnaparinmentioning

confidence: 99%

“…After intravenous administration E max is approximately 5-fold greater than after subcutaneous administration of the same dose (eg, mean E max 1.35 IU/mL after iv administration of 3200 IUaXa) 10,12. Parnaparin peak anti-Xa activity (t max ) occurs rapidly after administration, approximately 3 hours and 5 minutes when the subcutaneous or intravenous route are used, respectively, regardless of dose 10,12. Independently of the injection site (abdomen, gluteal region, deltoid), the bioavailability of the drug was > 90% 24,25.…”

Section: Pharmacology Of Parnaparinmentioning

confidence: 99%

“…Parnaparin peak anti-Xa activity (t max ) occurs rapidly after administration, approximately 3 hours and 5 minutes when the subcutaneous or intravenous route are used, respectively, regardless of dose 10,12. Independently of the injection site (abdomen, gluteal region, deltoid), the bioavailability of the drug was > 90% 24,25. No signs of drug accumulation after repeated once-daily subcutaneous administration for 7 days were detected 26…”

Section: Pharmacology Of Parnaparinmentioning

confidence: 99%

See 3 more Smart Citations

Update on the clinical use of the low-molecular-weight heparin, parnaparin

Camporese

Bernardi²,

Noventa³

2009

VHRM

View full text Add to dashboard Cite

Parnaparin is a low-molecular-weight heparin that has widely shown its efficacy and safety in prevention of venous thromboembolism, in the treatment of chronic venous disorders, and in the treatment of venous and arterial (stable and unstable angina, acute ST-segment elevation myocardial infarction) thrombosis. Parnaparin at the respective dosages of 3200, 4250, 6400, or 12800 IUaXa for a period ranging from 3 to 5 days to 6 months, is usually administered subcutaneously by means of once-daily regimen and is better tolerated than unfractionated heparin at the injection site. In the variety of commercially available low-molecular-weight heparins, parnaparin represents a useful therapeutic option, even though little evidence is available comparing the superiority or the equivalent efficacy and safety of parnaparin to that of the unfractionated heparin or placebo. This review summarizes the available literature on the use of parnaparin in different settings of cardiovascular diseases, including papers published during the past year and ongoing studies.

show abstract

Section: Pharmacology Of Parnaparinmentioning

confidence: 99%

Section: Pharmacology Of Parnaparinmentioning

confidence: 99%

Section: Pharmacology Of Parnaparinmentioning

confidence: 99%

Section: Pharmacology Of Parnaparinmentioning

confidence: 99%

See 2 more Smart Citations

Update on the clinical use of the low-molecular-weight heparin, parnaparin

Camporese

Bernardi²,

Noventa³

2009

VHRM

View full text Add to dashboard Cite

show abstract

“…In fact, it has been shown that, unlike traditional calcium heparin, low molecular weight heparins do not induce thrombopenia and reduce significantly the risk of haemorrhage.23 Another extremely interesting feature of these low molecular weight compounds is their high bioavailability after subcutaneous administration and their long-lasting action. 13 The combination of these physiopathological and clinical data fully justifies the current widespread use in medical practice of low molecular weight heparins in the prevention of deep vein thrombosis and thus in the treatment of thromboembolic disease.…”

Section: Introductionmentioning

confidence: 97%

Prevention of deep vein thrombosis in orthopaedic surgery. Comparison of two different treatment protocols with low molecular weight heparin (‘Fluxum’)

Laguardia

Caroli

1992

Current Medical Research and Opinion

View full text Add to dashboard Cite

The efficacy of two treatment protocols with a low molecular weight heparin used for the prevention of post-operative deep vein thrombosis was compared in 40 patients undergoing hip replacement surgery. The aim was to assess whether the different timing--2 hours before (Group A, 19 patients) or 2 hours after (Group B, 21 patients) the surgical operation--of the first dose administered (15,000 aXaU) of a therapeutic cycle of 7 days could affect the results, both with respect to the preventive efficacy and to the risk of haemorrhage often connected with antithrombotic therapy. The results showed that the incidence of deep vein thrombosis was very similar and extremely low in the two groups, only 1 patient in each group having a positive diagnosis on phlebography. The effectiveness of a single daily dose of 15,000 aXaU in orthopaedic surgery was also confirmed. This dose guaranteed effective prophylaxis against the onset of deep vein thrombosis and did not appear to have any local side-effects (such as burning or pain at the site of injection) which could diminish patient compliance.

show abstract

Industrial applications of polysaccharides

Lapasin

Pricl

1995

Rheology of Industrial Polysaccharides: Theory and Applications

View full text Add to dashboard Cite

The impact of polysaccharides in industrial applications is enormous!. The usefulness of these water-soluble carbohydrate polymers in industry undoubtedly relies on the wide range of their functional properties. Chief among polysaccharide characteristics is their ability to modify the properties or" aqueous environments, that is their capacity to thicken, chelate, emulsify, stabilize, encapsulate, flocculate, swell and suspend, or to form gels, films and membranes. Polysaccharides are natural polymers from renewable sources; therefore, peculiar features like biocompatibility, biodegradability, bioadhesivity and nontoxicity, coupled with wide availability and usually low costs, account for their steadily increasing exploitation in the formulation of products for food, biomedical and cosmetic applications.Polysaccharides, both natural gums and their derivatives, are classified as specialty chemicals. Quite generally, the term specialty chemicals refers to those products which are commercialized on the basis of their performance rather than their physical properties. These substances can be further divided into two main categories: the functional chemicals, which play a specific role in a variety of markets, and the market-directed chemicals, which are oriented to a specific field or application, and to which category polysaccharides generally belong. In the following sections we will briefly describe the principal industrial applications of polysaccharides. ! As in §1.3, the references cited in this chapter represent a selected list of papers and books which have appeared in literature mostly since 1988. R. Lapasin et al., Rheology of Industrial Polysaccharides: Theory and Applications © Springer Science+Business Media Dordrecht 1995 2.1.1 Polysaccharides infoods: function versus gum usedCarbohydrate polymers are widely used in food processing and preparation [1][2][3][4][5][6][7][8]. Sometimes they are present for technological reasons, e.g. as process aids, to stabilize emulsions and suspensions, and to give the physical structure required for packaging or distribution. More often, however, the thickening and gelling properties of these biopolymers are exploited to enhance or standardize the eating quality of a product [1].Many food products are emulsions, that is a mixture of two immiscible liquids in which one phase is dispersed throughout the other as small, discrete droplets. Polysaccharides can assist in obtaining a fine dispersion and in maintaining the homogeneous mixture; therefore, it is not always easy to distinguish between emulsifier and stabilizer [2]. Foams are related to emulsions, being a dispersion of gas (or gases) in a liquid (or solid), and polysaccharides can be conveniently used to modify the interfacial tension and obtain a stable, firm foam. Suspending agents are those substances that are used to uniformly disperse solid particles through a liquid phase, and the relative stabilizers help in preventing particle settling.A thickening agent, as the word implies, increases the viscosity of a l...

show abstract

Human pharmacology of a low‐molecular‐weight heparin (ALFA‐LMWH): An update

Cited by 12 publications

References 25 publications

Update on the clinical use of the low-molecular-weight heparin, parnaparin

Update on the clinical use of the low-molecular-weight heparin, parnaparin

Prevention of deep vein thrombosis in orthopaedic surgery. Comparison of two different treatment protocols with low molecular weight heparin (‘Fluxum’)

Industrial applications of polysaccharides

Contact Info

Product

Resources

About